
    
      The study design is based on a phase I / II trial in eight Spanish hospitals.

      In the phase I, a number of 3 to 12 patients will be included to evaluate the optimal dose of
      ixazomib in combination with sirolimus and tacrolimus.

      In the phase II, a total number of 130 patients will be randomized to receive ixazomib or the
      best medical recommendation added in order to evaluate the efficacy of ixazomib. This
      patients who will receive any prophylaxis for GVHD, except those patients who received
      antithymocyte globulin , cyclophosphamide or any T depletion protocol in vitro or in vivo.
    
  